<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201094</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00074174</org_study_id>
    <nct_id>NCT03201094</nct_id>
  </id_info>
  <brief_title>Impact of NMES and HPRO on Recovery After SAH- Pilot Study</brief_title>
  <official_title>Impact of Neuromuscular Stimulation and High Protein Nutritional Supplementation on Long-term Recovery After Aneurysmal Subarachnoid Hemorrhage.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to investigate the hypothesis that in adults with SAH, early&#xD;
      neuromuscular electrical stimulation (NMES) and high protein supplementation (HPRO) will&#xD;
      improve muscle mass, metabolic and inflammatory biomarker profiles, compared to SAH controls&#xD;
      receiving standard of care interventions for nutrition and mobilization. The investigators&#xD;
      will accomplish this by studying the effects of a high protein (HPRO) nutritional treatment&#xD;
      as well as NMES intervention have upon muscle wasting and motor strength acutely after SAH.&#xD;
      This will be addressed in a prospective trial of SAH patients receiving HRPO with NMES as&#xD;
      compared to age and severity-matched SAH patients undergoing standard of care interventions&#xD;
      for nutrition and mobilization. Additionally, the study will investigate the impact HPRO and&#xD;
      NMES interventions have upon inflammatory cytokines and markers of energy balance. Results of&#xD;
      this study will establish evidence for precision nutrition plus early exercise to mitigate&#xD;
      the catabolic and inflammatory state produced by SAH to improve muscle, metabolic, and health&#xD;
      recovery outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in muscle layer thickness of the quadriceps muscle as measured by muscle ultrasound scan at the end of study period.</measure>
    <time_frame>14 days</time_frame>
    <description>Change in the muscle layer thickness of the quadriceps muscle as measured by ultrasound.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <condition>Muscle Atrophy</condition>
  <condition>Inflammation</condition>
  <condition>Nutritional and Metabolic Disease</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive standard of care mobilization and nutritional supplementation throughout the study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HPRO + NMES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive high protein supplementation(HPRO) administered within 30 minutes after each NMES session and additionally once at approximately 10 PM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NMES only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo two 30 minute NMES sessions per day during study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HPRO only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive HPRO three times daily during study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuromuscular Electrical Stimulation (NMES)</intervention_name>
    <description>Neuromuscular electrical stimulation twice daily during study period.</description>
    <arm_group_label>HPRO + NMES</arm_group_label>
    <arm_group_label>NMES only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High Protein Supplementation</intervention_name>
    <description>High protein supplementation with whey protein shakes taken three times a day during study period.</description>
    <arm_group_label>HPRO + NMES</arm_group_label>
    <arm_group_label>HPRO only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. . Being diagnosed with aneurysmal SAH&#xD;
&#xD;
          2. . Aneurysmal repair within 48 hours of ictus.&#xD;
&#xD;
          3. . Age between 25 and 80 years old. (&gt;=25 years old and &lt;=80 years old)&#xD;
&#xD;
          4. . Expected stay in the NCCU &gt; 72 hours.&#xD;
&#xD;
          5. . Admission Hunt Hess Grade &gt;=2.&#xD;
&#xD;
          6. modified Fisher score &gt;1.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. . Subjects diagnosed with SAH from trauma, rupture of an arteriovenous malformation,&#xD;
             neoplasm, vasculitis, or other secondary causes;&#xD;
&#xD;
          2. . Unlikely to survive one week post hemorrhage either due to impending brain death or&#xD;
             likely request for withdrawal of care;&#xD;
&#xD;
          3. . Unlikely to remain in the ICU for more than 7 days;&#xD;
&#xD;
          4. . Body mass index &lt; 15 or &gt;40 kg/m2;&#xD;
&#xD;
          5. . Allergy to whey protein;&#xD;
&#xD;
          6. . Evidence of lower extremity paresis or spasticity within 48 hours of injury&#xD;
&#xD;
          7. . Pre-morbid modified Rankin Score &gt;1.&#xD;
&#xD;
          8. . Known pregnancy&#xD;
&#xD;
          9. . Presence of active malignancy&#xD;
&#xD;
         10. . Diagnosis of an inflammatory disorder&#xD;
&#xD;
         11. . Presence of a neuromuscular disorder&#xD;
&#xD;
         12. . Diagnosis of chronic renal insufficiency or acute kidney injury (GFR &lt; 30&#xD;
             mL/min/1.73m2)&#xD;
&#xD;
         13. . Hepatic insufficiency defined as AST/ALT levels &gt;2.5 above normal upper limits.&#xD;
&#xD;
         14. . On-going seizure activity as assessed clinically or by electrographic detection on&#xD;
             continuous electroencephalogram (cEEG) at time of enrollment&#xD;
&#xD;
         15. . Prisoner.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neeraj Badjatia, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neeraj Badjatia, MD MSc</last_name>
    <phone>4103284515</phone>
    <email>nbadjatia@umm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neeraj Badjatia, MD MS</last_name>
      <phone>410-328-4515</phone>
      <email>nbadjatia@umm.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, College Park</investigator_affiliation>
    <investigator_full_name>Neeraj Badjatia</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

